Resonance Health Ltd
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Resonance Health boosts FY26 cash to net $2.3m, receipts $14.3m; pipeline over $12m as MRI liver fibrosis trial recruitment completes.
Resonance Health expands clinical trial operations with Sun Pharmaceutical agreement
Australian healthcare technology and services company Resonance Health (ASX: RHT) has secured an agreement with Sun Pharmaceutical Industries to operate as its local Australian sponsor. As sponsor, Resonance will provide clinical research organisation, trial site and imaging analysis services for the global pharmaceutical giant’s Australian clinical trial of a new drug compound. Resonance estimates it […]
Resonance Health to acquire TrialsWest in $8m deal, expands global clinical trial reach
Perth-based Resonance Health (ASX: RHT) has secured a deal to acquire private clinical trial site and research centre TrialsWest, representing a major step forward in its growth strategy. TrialsWest is one of Australia’s most experienced clinical research centres, partnering with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and […]
Resonance Health’s FerriSmart MRI iron detection technology to be marketed in US
Resonance Health’s (ASX: RHT) “gold standard” FerriSmart magnetic resonance imaging service will be marketed and sold in the United Stated via an agreement with Accumen subsidiary 3DR Laboratories. FerriSmart uses artificial intelligence to analyse MRI images and report on liver iron concentrations within seconds. According to Accumen, the technology enables practitioners to effectively and efficiently […]